This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Classification of pulmonary hypertension

Authoring team

The clinical classification is helpful in understanding the different aetiology and determining treatment

  • Group 1 Pulmonary arterial hypertension (PAH)
    • idiopathic PAH
    • PAH associated with connective tissue disease: predominantly seen with scleroderma

  • Group 2 Left heart disease
    • PH associated with left heart dysfunction, systolic, diastolic or valve disease

  • Group 3 Lung disease
    • PH in patients with COPD or interstitial lung disease

  • Group 4 Chronic thromboembolic pulmonary hypertension

  • Group 5 Unclear and multifactorial mechanisms
    • Rare diseases

  • Groups 2 and 3 contain the majority of patients, but in these patients with common medical diseases the underlying condition needs treatment, usually by cardiologists and respiratory physicians respectively. Patients in groups 1 and 4 should be referred for specific treatment by PH specialists in the UK national designated centres

Reference:

  • 1) British Heart Foundation (August 2012). Factfile: pulmonary hypertension

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.